Colorado Cancer Therapeutics (CCT), Arch Biopartner's majority owned American subsidary, was formed to acquire and develop anti-cancer compounds. CCT has acquired an option to enter into an exclusive license to commercialize a new class of anticancer compounds invented at the University of Colorado and Emory University by Drs. Lajos Gera, Robert Hodges, Paul Bunn, John Stewart, Dan Chan, Leland Chung and Daqing Wu.
(the "Option")
In pre-clinical studies involving mice, these compounds have shown efficacy in slowing the progression of certain forms of pancreatic cancer, non small cell lung cancer, and prostate cancer.
As pre–conditions to exercising the Option, Arch will perform further pre-clinical validation studies and assess the commercial viability of the technology. Twelve compounds are currently in the various stages of pre-clinical testing. The focus is to identify a lead compound and formulate a drug development plan. Arch will have up to January 1, 2012 to complete this assessment and exercise the Option. |
